title: TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
abstract: Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). We found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.
authors: Institute of Immunology, Medical Faculty, Technical University of Dresden, Dresden, Germany.
authors: Hanka
authors: H
authors: Jähnisch
authors: Rebekka
authors: R
authors: Wehner
authors: Antje
authors: A
authors: Tunger
authors: Anja
authors: A
authors: Kunze
authors: Stephanie
authors: S
authors: Oehrl
authors: Knut
authors: K
authors: Schäkel
authors: Jacques
authors: J
authors: Rohayem
authors: Martin
authors: M
authors: Bornhäuser
authors: Torsten
authors: T
authors: Tonn
authors: Michael
authors: M
authors: Bachmann
authors: Marc
authors: M
authors: Schmitz
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D051940:B7-2 Antigen / Q000378:metabolism; D049109:Cell Proliferation; D018920:Coculture Techniques; D016207:Cytokines / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D004354:Drug Screening Assays, Antitumor; D006684:HLA-DR Antigens / Q000378:metabolism; D019073:HT29 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D000077271:Imiquimod; D007136:Immunoglobulins / Q000378:metabolism; D056747:Immunomodulation / Q000187:drug effects; D018836:Inflammation Mediators / Q000378:metabolism; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D051199:Toll-Like Receptor 7 / Q000819:agonists* / Q000378:metabolism; D051200:Toll-Like Receptor 8 / Q000819:agonists* / Q000378:metabolism; D000097802:CD83 Antigen
chemical_list: D000634:Aminoquinolines; D015703:Antigens, CD; D000970:Antineoplastic Agents; D051940:B7-2 Antigen; D016207:Cytokines; D006684:HLA-DR Antigens; D007093:Imidazoles; D000077271:Imiquimod; D007136:Immunoglobulins; D018836:Inflammation Mediators; D008562:Membrane Glycoproteins; D051199:Toll-Like Receptor 7; D051200:Toll-Like Receptor 8; D000097802:CD83 Antigen; C497964:CD86 protein, human; C495348:TLR7 protein, human; C495349:TLR8 protein, human; C402365:resiquimod